According to the American Diabetes Association’s Standards of Medical Care in Diabetes—2020, basal insulin including intermediate-acting human insulin (IAHI) and long-acting insulin analogue (LAIA), is suggested for patients with type 2 diabetes (T2D) who require initiation of insulin therapy1. The gene discussed is INS; the disease is type 2 diabetes mellitus.